News & Updates

107, 2020

General Standby Statement

July 1st, 2020|

Agendia, Inc. has entered into a Settlement Agreement with the U.S. Department of Justice (DOJ) acting on behalf of the Office of Inspector General of the Department of Health and Human Services (OIG-HHS) to resolve Read More

2905, 2020

Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment

May 29th, 2020|

PRESS RELEASE Presentations outline how BluePrint​®​ genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to Read More